Upgrade to SI Premium - Free Trial

Galmed Pharma (GLMD) Says ARRIVE Trial Did Not Meet its Primary Endpoint

February 14, 2018 7:18 AM
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("GalmedĖ® or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles